Racura Oncology, University of Wollongong Win New South Wales Government Funding for Cancer Study
MT Newswires Live
Apr 29
Racura Oncology (ASX:RAC) and the University of Wollongong secured funding under the New South Wales government's TechVouchers program to study the efficacy of (E,E)-bisantrene for certain types of breast and ovarian cancers, according to a Wednesday filing with the Australian bourse.
A collaboration between Racura and the University aims to produce preclinical evidence for the development of RC220 as a new targeted therapy, per the filing.
Results from the collaboration are expected to come out over the next 12 months.
Racura Oncology shares gained 2% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.